Skip to content
Towards Lab-Free TB Diagnosis Report Cover

Towards a Lab-Free Tuberculosis Diagnosis

A strategic vision for R&D into point-of-care testing in resource-poor settings Tuberculosis (TB) remains a major challenge to public health globally, particularly in resource-poor settings. August 2011 – Although most cases of TB are curable, tuberculosis causes around 2 million…

Read more

Cepheid Pricing Of GeneXpert

On November 12, 2010, the Treatment Action Campaign (TAC) and partners jointly sent an open letter to Cepheid calling for affordable and expanded access to the GeneXpert® MTB/RIF TB diagnostic test. Following this correspondence, TAC and partners had a teleconference with FIND and Cepheid, during which Cepheid indicated that prices for the GeneXpert would be reduced. During December, FIND announced that it had negotiated a volume-based price reduction agreement with Cepheid, lowering the cost of the GeneXpert.
Read more

Poor progress means multidrug-resistant tuberculosis continues to spread and cost lives

The global response to help countries scale up treatment of multidrug-resistant tuberculosis (MDR-TB) is underfunded and ineffective, according to a new report released today by three medical and medical advocacy organisations. A 20-month effort to reform the Green Light Committee Initiative, a World Health Organization (WHO)-hosted programme designed to help countries gain technical support for scale up of MDR-TB and access to quality-assured MDR-TB drugs, needs to be closely monitored to see if the reforms will address many key bottlenecks.
Read more

Time for a Bold New Vision at the Stop TB Partnership

From The Lancet, Volume 376, Issue 9749, Pages 1283 - 1284, 16 October 2010 Salmaan Keshavjee,a,b,c Francoise Girard,d Mark Harrington,e Paul E Farmera,b,c Tuberculosis—a curable infectious disease—continues to cause illness in more than 9 million people annually. In the past…

Read more

2010 Pipeline Report

HIV, Tuberculosis, and Viral Hepatitis: Drugs, diagnostics, Vaccines, Immune-based therapies, and Preventive Technologies in Development. By Polly Clayden, Lei Chou, Simon Collins, Mark Harrington, Richard Jefferys, Eleonora Jimenez, Scott Morgan, Tracy Swan, Javid Syed and Claire Wingfield.
Read more

2009 Report on TB Research Funding Trends

2009 TB Research Funding Trends, 2005 - 2008 - Second Edition March 2010 - This is an update to Treatment Action Group’s 2009 report on funding trends for tuberculosis (TB) research and development (R&D) from the baseline year 2005 through…

Read more
Back To Top